ClinicalTrials.gg
CompletedNCT01448317Updated Sep 28, 2016

Ascending Dose Study of the Safety and Tolerability of Alirocumab (SAR236553/REGN727) in Japanese Healthy Volunteers

A Phase 1 interventional study of Alirocumab (Solution) and Alirocumab (Lyophilized formulation) in Hypercholesterolemia, sponsored by Sanofi. Completed at 1 site in Japan. Open to male participants aged 20 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-09-28.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.

Enrollment
35th of 43
32 · median 107
Started
2011
with 6 others
Phase 1
9 of 43
none open now
Registered
5th of 43
by date
Lead sponsor
28 of 43
Sanofi

Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 35th largest by enrollment, is one of 7 that started in 2011, is one of 9 in phase 1, and was the 5th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About alirocumab

alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 20 Years to 65 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing alirocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

Primary Objective:

To assess the safety and tolerability of ascending single doses of subcutaneously (SC) administered alirocumab (SAR236553/REGN727) in Japanese healthy male subjects.

Secondary Objectives:

  • To assess the pharmacodynamics effect of a single SC dose of alirocumab on serum low-density lipoprotein cholesterol (LDL-C) and other lipids and apolipoproteins such as total cholesterol, high-density lipoprotein cholesterol (HDL-C), non-high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol, Triglycerides, Apolipoprotein B, Apolipoprotein A1 and Lipoprotein(a).
  • To assess the Pharmacokinetic profile of a single SC dose of alirocumab.
  • To assess the immunogenicity of a single SC dose of alirocumab.
Read the detailed description

4 sequential dose cohorts. Single dose followed by a total observation period of 15 weeks (106 days) for each participant.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subject, between 20 and 65 years inclusive.
  • Body weight between 50.0 and 95.0 kg inclusive, between 18.0 and 30.0 kg/m² inclusive.
  • Serum LDL-C levels >100 mg/dL

Exclusion criteria

Exclusion Criteria:

  • Subject indicated for the use of statins according to criteria in Adult Treatment Panel (ATP) III Guidelines as updated in 2004
  • Significant concomitant illness or history of significant illness such as cardiac, renal, neurological, endocrinological, dermatological, metabolic or lymphatic disease, or any other illness or condition that would adversely affect the subject's participation in this study.
  • History or presence of drug or alcohol abuse
  • Smoking more than 5 cigarettes or equivalent in any 24 hour period.
  • Any medication (including St John's Wort) within 14 days before the inclusion or within 5 times the elimination half-life or pharmacodynamic (PD) half-life of that drug, whichever the longest; any vaccination within the last 28 days.
  • Positive reaction to any of the following tests: surface (HBs Ag) antigen, anti-hepatitis B core antibodies (anti-HBc Ab), anti- virus (anti-HCV) antibodies, (HIV) antigen and antibodies, syphilis.
  • Elevated cholesterol due to a secondary cause such as hypothyroidism or alcohol.
  • Presence or history of drug
  • Initiation of a new exercise routine or major change to a previous exercise routine within 4 weeks prior to Screening.
  • Initiation of a new diet or major change to a previous diet within 4 weeks prior to Screening.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Alirocumab dose 1 versus placebo

    Drug: Alirocumab (Lyophilized formulation) · Drug: Placebo (Lyophilized formulation)

  • Experimental
    Cohort 2

    Alirocumab dose 2 versus placebo

    Drug: Alirocumab (Lyophilized formulation) · Drug: Placebo (Lyophilized formulation)

  • Experimental
    Cohort 3

    Alirocumab dose 3 versus placebo

    Drug: Alirocumab (Lyophilized formulation) · Drug: Placebo (Lyophilized formulation)

  • Experimental
    Cohort 4

    Alirocumab dose 4 versus placebo

    Drug: Alirocumab (Solution) · Drug: Placebo (Solution)

Interventions

  • Pharmaceutical form: solution Route of administration: subcutaneous

    Also known as: SAR236553, REGN727

  • Pharmaceutical form: lyophilized formulation Route of administration: subcutaneous

    Also known as: SAR236553, REGN727

  • DrugPlacebo (Solution)

    Pharmaceutical form: solution Route of administration: subcutaneous

  • DrugPlacebo (Lyophilized formulation)

    Pharmaceutical form: lyophilized formulation Route of administration: Subcutaneous

06

What researchers measure

Primary outcomes

  1. Number of participants with Adverse Events

    Time frame: 106 days

Secondary outcomes

  1. Change in serum Low-Density Lipoprotein Cholesterol (LDL-C) from baseline to each visit.

    Time frame: 106 days

  2. Change in ApolipoproteinB, ApolipoproteinA1 and Lipoprotein(a) from baseline to each visit.

    Time frame: 106 days

  3. Change in Total Cholesterol (T-C), High-Density Lipoprotein Cholesterol (HDL-C), Very Low-Density Lipoprotein Cholesterol (VLDL-C) and Triglycerides (TG) from baseline to each visit.

    Time frame: 106 days

07

Study locations

1 site
  • Sanofi-Aventis Administrative Office
    Tokyo, Japan
08

References and documents

Publications

  • Teramoto T, Kobayashi M, Uno K, Takagi Y, Matsuoka O, Sugimoto M, Inoue S, Minami F, Baccara-Dinet MT. Efficacy and Safety of Alirocumab in Japanese Subjects (Phase 1 and 2 Studies). Am J Cardiol. 2016 Jul 1;118(1):56-63. doi: 10.1016/j.amjcard.2016.04.011. Epub 2016 Apr 21. PubMed 27184170 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2011, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2011
First posted
Oct 7, 2011
Start
May 2011
Primary completionActual
Jan 2012
CompletionActual
Jan 2012
Last update
Sep 28, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01448317
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Oct 7, 2011
Start date
May 2011
Primary completion
Jan 2012
Completion
Jan 2012
Last update
Sep 28, 2016

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alirocumab

Start the discussion